Published in Mol Cancer Ther on August 26, 2013
Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat (2013) 1.13
Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget (2015) 1.12
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature (2015) 1.03
The integrated stress response. EMBO Rep (2016) 0.96
Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation. PLoS One (2014) 0.90
Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene (2015) 0.86
Arginine dependence of tumor cells: targeting a chink in cancer's armor. Oncogene (2016) 0.86
MiR-21: an environmental driver of malignant melanoma? J Transl Med (2015) 0.82
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. Cancer Discov (2016) 0.82
Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer (2016) 0.80
Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. Oncotarget (2015) 0.77
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy. J Cancer Res Clin Oncol (2014) 0.76
A metabolic link between the urea cycle and cancer cell proliferation. Mol Cell Oncol (2016) 0.75
Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1. Cell Rep (2016) 0.75
Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect. Mol Cell Oncol (2017) 0.75
Drug-induced amino acid deprivation as strategy for cancer therapy. J Hematol Oncol (2017) 0.75
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A (2007) 15.88
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol (2010) 11.19
Genomic targets of the human c-Myc protein. Genes Dev (2003) 9.67
Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol (2005) 9.27
Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 7.79
Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans (2006) 7.69
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 7.30
The c-Myc target gene network. Semin Cancer Biol (2006) 5.98
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev (2008) 4.40
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A (2011) 2.14
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res (2009) 1.88
Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol (2011) 1.81
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer (2004) 1.78
AMP-activated protein kinase: new regulation, new roles? Biochem J (2012) 1.75
Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle (2010) 1.70
Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr (2012) 1.70
Nutrient sensing, metabolism, and cell growth control. Mol Cell (2013) 1.67
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer (2010) 1.66
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol (2011) 1.65
Therapeutic targeting of cancer cell metabolism. J Mol Med (Berl) (2011) 1.62
Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer (2002) 1.55
Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med (2011) 1.54
Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther (2007) 1.54
Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene (2009) 1.52
Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem (2009) 1.48
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther (2009) 1.37
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res (2012) 1.29
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem (2012) 1.27
Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Mol Cancer Ther (2012) 1.27
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer (2010) 1.23
Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. Nitric Oxide (2001) 1.16
Control of translation initiation through integration of signals generated by hormones, nutrients, and exercise. J Biol Chem (2010) 1.15
AMP-activated protein kinase phosphorylates cardiac troponin I and alters contractility of murine ventricular myocytes. Circ Res (2012) 1.14
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs (2012) 1.12
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget (2010) 1.09
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer (2012) 1.06
Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease. Cancer (1958) 0.96
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. Invest New Drugs (2012) 0.93
Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPKalpha1. Carcinogenesis (2010) 0.91
Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. Transl Oncol (2012) 0.87
Temsirolimus. Recent Results Cancer Res (2010) 0.77
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 3.81
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res (2004) 2.88
Rice plants take up iron as an Fe3+-phytosiderophore and as Fe2+. Plant J (2006) 2.82
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J (2007) 2.52
High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging (2005) 1.97
The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev (2007) 1.96
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol (2005) 1.88
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther (2004) 1.82
Rice metal-nicotianamine transporter, OsYSL2, is required for the long-distance transport of iron and manganese. Plant J (2010) 1.66
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 1.55
Mutational reconstructed ferric chelate reductase confers enhanced tolerance in rice to iron deficiency in calcareous soil. Proc Natl Acad Sci U S A (2007) 1.54
Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther (2007) 1.54
Biosynthesis and secretion of mugineic acid family phytosiderophores in zinc-deficient barley. Plant J (2006) 1.41
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer (2005) 1.41
Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs (2006) 1.39
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther (2009) 1.37
2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol (2010) 1.35
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res (2008) 1.30
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res (2012) 1.29
Synthesis and biological evaluation of D-amino acid oxidase inhibitors. J Med Chem (2008) 1.29
Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia. Curr Pharm Des (2011) 1.28
Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry (2009) 1.27
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem (2012) 1.27
Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs (2010) 1.25
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res (2003) 1.24
Deoxymugineic acid increases Zn translocation in Zn-deficient rice plants. Plant Mol Biol (2008) 1.22
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther (2007) 1.22
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol (2014) 1.21
Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol (2002) 1.20
Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol (2009) 1.19
Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A (2003) 1.18
Transcription factor Sp1 plays an important role in the regulation of copper homeostasis in mammalian cells. Mol Pharmacol (2008) 1.16
Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol (2002) 1.15
Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. J Neurochem (2007) 1.13
Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem (2003) 1.12
Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer (2011) 1.12
FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat Commun (2012) 1.12
Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem (2009) 1.10
Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol (2008) 1.09
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget (2010) 1.09
Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem (2007) 1.08
Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas (2005) 1.08
Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol (2011) 1.07
Reduced BACE1 activity enhances clearance of myelin debris and regeneration of axons in the injured peripheral nervous system. J Neurosci (2011) 1.06
Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res (2012) 1.05
Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern--synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives. Eur J Med Chem (2003) 1.03
Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol (2008) 1.03
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice. Drug Metab Dispos (2012) 1.02
Overcoming platinum resistance through the use of a copper-lowering agent. Mol Cancer Ther (2012) 1.01
Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol (2008) 1.01
Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther (2012) 1.01
p27(Kip1) as a prognostic factor in breast cancer: a systematic review and meta-analysis. J Cell Mol Med (2010) 1.00
Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol (2003) 0.98
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights (2007) 0.96
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther (2008) 0.96
Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol (2003) 0.95
Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol (2007) 0.94
Synthesis and SAR of 1-hydroxy-1H-benzo[d]imidazol-2(3H)-ones as Inhibitors of D-Amino Acid Oxidase. ACS Med Chem Lett (2012) 0.94
Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog (2006) 0.94
Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem (2006) 0.93
The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun (2010) 0.92
Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg (2010) 0.92
Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs. Bioorg Med Chem Lett (2011) 0.92
Merkel cell carcinomas. Hematol Oncol Clin North Am (2007) 0.91
The dapE-encoded N-succinyl-l,l-diaminopimelic acid desuccinylase from Haemophilus influenzae is a dinuclear metallohydrolase. J Am Chem Soc (2003) 0.91
Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. Adv Exp Med Biol (2006) 0.91
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. Biochem Biophys Res Commun (2013) 0.89
Elevated GSH level increases cadmium resistance through down-regulation of Sp1-dependent expression of the cadmium transporter ZIP8. Mol Pharmacol (2008) 0.89
Redox regulation of matrix metalloproteinase gene family in small cell lung cancer cells. Free Radic Res (2005) 0.88
Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. Cancer Res (2013) 0.87
Synthesis of kojic acid derivatives as secondary binding site probes of D-amino acid oxidase. Bioorg Med Chem Lett (2013) 0.86
Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett (2003) 0.86
Arginine deprivation in cancer therapy. Curr Opin Clin Nutr Metab Care (2015) 0.86
Topoisomerase I inhibitors for the treatment of brain tumors. Expert Rev Anticancer Ther (2008) 0.85
TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem (2012) 0.85
The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther (2012) 0.85
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs (2013) 0.84
N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers (Basel) (2009) 0.84